To explore whether the association of antiplatelets with faster AAA growth at the class level might relate to greater use in individuals not taking other cardiovascular medications, the percentage of drug reports involving ACE inhibitors, ARBs, metformin, and thiazides was calculated, for individuals who reported taking antiplatelets. Here, ACE is linked to triple-A syndrome.